Submission of Un-Audited Standalone Financial Results for the Quarter ended as on June 30, 2026
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 14 Aug 2026, 12:59 PM IST · BSE ID: 08c911b4-0732-4479-b79a-60c1a1dffe3f
View Original BSE Filing (PDF)
💡
In Simple Terms
Godavari Drugs announced its first quarter financial results, showing increased profit and revenue compared to the same period last year.
🤖 AI Summary
- Godavari Drugs reported Q1 FY27 standalone net profit of Rs. 110.91 Lakhs.
- This represents a 6.58% increase compared to Rs. 104.06 Lakhs in Q1 FY26.
- Revenue from operations for Q1 FY27 reached Rs. 2795.72 Lakhs.
- Basic Earnings Per Share (EPS) for the quarter ended June 30, 2026, was Rs. 1.10.
- Board of Directors approved the unaudited financial results on August 14, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from operations (Q1 FY27)
2795.72 Lakhs
17.49%
Net Profit for the period (Q1 FY27)
110.91 Lakhs
6.58%
Basic Earnings per share (Q1 FY27)
1.10
-20.29%
Paid-up equity share capital
1012.74 Lakhs
🏢 How This Affects the Company
Revenue from operations increased by 17.49% year-over-year, indicating growth in core business activities for the quarter.
Net profit for the period increased to Rs. 110.91 Lakhs from Rs. 104.06 Lakhs year-over-year, improving profitability margins.
Changes in inventories of finished goods & work-in-progress showed a larger negative figure (-634.45 Lakhs) compared to prior year (-85.41 Lakhs), impacting cost of goods sold.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results filing.
👤
Who Is Affected
Shareholders will see their Basic Earnings Per Share (EPS) at Rs. 1.10 for Q1 FY27, compared to Rs. 1.38 in Q1 FY26, reflecting the impact of increased paid-up equity share capital from Rs. 753.05 Lakhs to Rs. 1012.74 Lakhs.
🔍
Management Signal
The approval of the unaudited results indicates management's adherence to regulatory financial reporting timelines and disclosure requirements.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 financial results — check for sustained revenue and profit growth.
Review of paid-up capital changes — assess future EPS trends.
Analysis of inventory changes — understand impact on cost of materials.
MEDIUM RISK
EPS decline despite profit growth due to capital increase; large inventory changes observed.
💡 Investor Takeaway
Godavari Drugs reported Q1 FY27 net profit of Rs. 110.91 Lakhs, a 6.58% increase from Rs. 104.06 Lakhs in Q1 FY26. Revenue from operations rose 17.49% to Rs. 2795.72 Lakhs. Basic EPS decreased to Rs. 1.10 from Rs. 1.38, impacted by higher paid-up capital.
⚖️ Strengths & Concerns
✅ Positives
- Net Profit for Q1 FY27 increased to Rs. 110.91 Lakhs, up 6.58% compared to Rs. 104.06 Lakhs in Q1 FY26.
- Revenue from operations grew by 17.49% to Rs. 2795.72 Lakhs in Q1 FY27 from Rs. 2381.13 Lakhs in Q1 FY26.
⚠️ Concerns
- Basic EPS for Q1 FY27 decreased to Rs. 1.10 compared to Rs. 1.38 in Q1 FY26, despite higher net profit.
- The negative change in inventories of finished goods and work-in-progress significantly deepened to -634.45 Lakhs from -85.41 Lakhs YoY.
📅 Company Track Record
In its Board Meeting on May 27, 2026, Godavari Drugs approved financial results for FY26, reporting a Net Profit of Rs. 408.91 Lakhs, which was a 6.64% decrease year-over-year.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Godavari Drugs' net profit for the quarter ended June 30, 2026?
Godavari Drugs reported a standalone net profit of Rs. 110.91 Lakhs for the quarter ended June 30, 2026.
How did Godavari Drugs' revenue from operations change year-over-year in Q1 FY27?
Revenue from operations for Q1 FY27 increased to Rs. 2795.72 Lakhs, up 17.49% from Rs. 2381.13 Lakhs in Q1 FY26.
What was the Basic Earnings per share (EPS) for Godavari Drugs in Q1 FY27?
The Basic Earnings per share for Godavari Drugs for the quarter ended June 30, 2026, was Rs. 1.10.
What was the paid-up equity share capital of Godavari Drugs as of June 30, 2026?
The paid-up equity share capital of Godavari Drugs as of June 30, 2026, was Rs. 1012.74 Lakhs.
Questions based on this BSE filing only. For information purposes.